Catalyst Dossier · compiled by CeliA 🧫

Theriva Biologics, Inc. (TOVX)

Pharmaceutical Preparations · market cap $12M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Theriva Biologics, Inc. (TOVX) is a micro-cap pharmaceutical company with a market capitalization of approximately $12M and a stock price near $0.24. The company maintains a pipeline spanning gastrointestinal and oncology indications, including SYN-004, SYN-010, and a nab-paclitaxel program for pancreatic adenocarcinoma, all at Phase 2 stage. No upcoming catalysts are on the calendar and no recent catalysts have been disclosed, leaving the investment case largely speculative.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)	Phase 2	Pancreas Cancer, Metastatic
Period 1 - Treatment Sequence AB	Phase 2	Healthy Volunteers
SYN-004	Phase 2	Healthy Volunteers With Ileostomy
SYN-010	Phase 2	Irritable Bowel Syndrome With Constipation (IBS-C)
SYN-010 21 mg	Phase 2	Irritable Bowel Syndrome With Constipation (IBS-C)
Nab-paclitaxel	Phase 2	Pancreatic Adenocarcinoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TOVX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.